Safety and efficacy of BCMA CAR-T vs. bispecific antibodies in patients with relapsed multiple myeloma: a systematic review and meta-analysis

Key Points

• BCMA CAR-T therapy demonstrates a significant improvement in patient outcomes compared to bispecific antibodies.
• The meta-analysis reveals a notable efficacy difference, particularly in relapse rates for patients with advanced disease.
• Systematic review comparing clinical outcomes from several studies highlights the benefits of CAR-T cells in modifying the immune response.
• Findings suggest both therapies are viable, but CAR-T may provide added survival advantages; further validation is needed.